ReviewRheumatology international2025
Ηidradenitis suppurativa associated with autoimmunity in children and adolescents; a case-based review.
Review in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management Considerations for Patients with Hidradenitis Suppurativa and Lupus Spectrum Disease: A Narrative Review.Dermatology and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hidradenitis suppurativa (HS) is an uncommon chronic inflammatory disease in children, characterized by painful abscesses and lesions. It has been associated with various autoimmune conditions, including inflammatory bowel diseases (IBDs) and rheumatologic disorders. We present a 13-year-old female with Hurley stage III HS, who developed macrophage activation syndrome (MAS). Clinical presentation and laboratory findings led to a diagnosis of systemic lupus erythematosus (SLE). Treatment with immunosuppressive therapy resulted in symptom resolution and clinical improvement. In addition, a case-based review was conducted to evaluate the patterns, clinical features and possible underlying mechanisms in the pediatric patients with HS and autoimmune diseases. Twenty pediatric cases were included with a median HS onset age of 15 years (IQR: 4 years). Among these, 55% were diagnosed with IBDs, followed by autoimmune arthritis and psoriasis (10% each). Treatment was individualized, with 95% receiving biologic agent and 55% receiving antimicrobials. This case and case-based review of literature highlight the potential overlap between HS and autoimmunity, especially SLE, in the pediatric population and emphasize the importance of proactive monitoring for coexisting autoimmune diseases in patients with HS, in order to facilitate early detection and effective management.
Indexed as
Identifiers
40153074What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.